Michael Ertl: Air Pollution and Stroke – Which Patients Are Particularly at Risk?
Michael Ertl, Medical Director and Chief Physician at District Hospitals of Swabia, shared on LinkedIn about a recent article he and his colleagues co-authored, published in Air Quality, Atmosphere and Health, adding:
”Air pollution and stroke: Which patients are particularly at risk?
I am pleased that our current work from our research group has now been published:
‘The influence of ambient air pollutants on stroke occurrence: a clinically relevant prospective study’
In a prospective analysis of more than 3,100 consecutive stroke patients, we investigated how short-term exposure to air pollutants is related to the occurrence of strokes – and whether certain clinical subgroups are particularly vulnerable.
Key results:
- NO₂ (nitrogen dioxide) showed the strongest associations with stroke events.
- Patients with macroangiopathy, diabetes mellitus and arterial hypertension were particularly affected.
- Particulate matter (PM₁₀) levels were associated with an increased risk of severe stroke, especially in patients requiring thrombectomy.
- The results suggest that air pollutants are not only a public health issue, but also have direct clinical relevance for neurological care.
The study is based on a prospective stroke registry with detailed clinical phenotyping and provides new clues as to which patient groups may be particularly sensitive to environmental exposure.
Many thanks to all co-authors as well as to the entire team that made the data collection and analysis possible.”
Title: The influence of ambient air pollutants on stroke occurrence: a clinically relevant prospective study
Authors: Bin Zhou, Lino Braadt, Jiancong Wang, Susanne Knöpfle, Melanie Stapf, Markus Naumann, Christoph Knote, Michael Ertl
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 3, 2026, 11:21Thrombotic Microangiopathies: From Clinical Syndrome to Molecularly Targeted Therapy
-
Sep 3, 2026, 10:56Elias Othman: Can an Enzyme Involved in Cell Signaling Become a Target for Antithrombotic Drug Discovery?
-
Sep 3, 2026, 10:42Jared Griffard: Hemorrhagic Shock and Component Blood Transfusion
-
Sep 3, 2026, 10:31Alan Nurden: Comparing Antiplatelet and Antithrombin Therapies in Coronary Microcirculation
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease